Latest Healthcare News

Echo IQ Limited has secured FDA clearance for its EchoSolv AS technology and appointed a US-based CEO, marking a pivotal shift towards commercialisation in the American healthcare market.

HITIQ Limited has extended its Premier League partnership by 18 months with a 60% contract value increase, appointed a new Chief Marketing Officer, and raised an additional $3 million to accelerate global growth.

Radiopharm Theranostics has secured key ethics approvals to expand its clinical trial portfolio, completed significant preclinical milestones, and raised A$8 million through a strategic placement, while maintaining its cash runway to mid-2026.

InteliCare advances its AI-driven platform deployment across multiple Hardi Aged Care sites, while expanding its commercial pipeline and enhancing product capabilities.

InteliCare Holdings Limited reported a positive net cash flow of $30,000 for the December quarter, buoyed by a substantial government R&D rebate. The company ends the quarter with $1.26 million in cash, signaling operational stability amid ongoing funding evaluations.

Unith Ltd has reported its strongest quarterly revenue in two years, driven by its B2C subscription division and strategic partnerships, while advancing its Digital Human technology and expanding into new markets.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Visionflex Group reported an 8% increase in Annual Recurring Revenue to $1.6 million in Q2 FY25 despite an 11% revenue decline, securing key contracts with Spark Health, BUPA, and Indigenous Wellness Connect. The company targets EBITDA profitability by Q4 FY25 amid a maturing sales pipeline.

Visionflex Group Limited reported a net cash outflow from operations for the December 2024 quarter but secured significant financing, extending its funding runway to nearly 15 quarters.

Mach7 Technologies has initiated a A$5 million on-market share buy-back program, reflecting confidence in its robust financial health and growth outlook. The move underscores the company’s commitment to capital management amid reaffirmed FY25 revenue growth guidance.

Imagion Biosystems has secured a AU$3 million capital injection and resumed its collaboration with Siemens, setting the stage to prioritize FDA filings and advance its MagSense® HER2 breast cancer imaging program.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.